Descripción de la empresa
Protara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing transformative therapies designed for the treatment of cancer and rare diseases. The company functions within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant capital requirements for research and development before commercialization occurs. With a market capitalization of $277.99M and an employee count of 46, the firm maintains a lean operational structure typical of early-stage biotech firms. The absence of reported annual revenue (N/A) alongside a market cap of $277.99M indicates that the company's valuation is driven primarily by potential future milestones and clinical trial data rather than current cash flows from product sales, reflecting its position as a pre-commercial asset.
Salud financiera
The company reports a Net Income of $-57,439,000 and an EBITDA of $-64,187,000, while annual Revenue remains N/A, revealing a cost structure where operating expenses vastly exceed any generated income. The Free Cash Flow stands at $-38,476,124, indicating that the company is consuming cash reserves to fund its clinical development programs rather than generating surplus liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability and is operating in a loss-making phase common for clinical-stage entities. On the liability side, the company holds $155.55M in Cash against $3.36M in Debt, resulting in a Debt to Equity ratio of 1.71 which suggests a leveraged balance sheet relative to equity, though the absolute debt level is low compared to cash holdings. The Current Ratio is an exceptionally high 14.58, indicating robust short-term liquidity and a strong ability to cover current liabilities with its available assets. Finally, the Return on Equity is -31.6% and the Return on Assets is -20.6%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a condition expected during the drug development phase.
Evaluación de valoración
The Trailing Twelve Month P/E Ratio is N/A due to negative earnings, while the Forward P/E is -3.70, implying that the market prices the stock based on anticipated future earnings normalization rather than historical performance. The Price to Book ratio is 1.40, suggesting that the market values the company at 40% above its net asset value, a premium that reflects the potential value of its intellectual property and pipeline. The Price to Sales ratio is N/A and the EV/EBITDA is -1.96, indicating that traditional sales-based or earnings-based valuation multiples are not applicable, forcing reliance on asset-backed or clinical milestone valuations. The 52-week trading range spans from a low of $2.77 to a high of $7.82, providing a clear band of historical volatility within which the current price must be evaluated. The Beta is 1.50, which indicates that the stock price exhibits 50% higher volatility than the broader market, meaning it is significantly more sensitive to market movements and sector-specific news.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of earnings growth relative to revenue expansion at this stage of the company's lifecycle. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders, opting instead to reinvest all available capital into research, development, and clinical trials. This reinvestment strategy is characteristic of clinical-stage biopharmaceutical companies that prioritize growth and asset appreciation over current income generation for investors. Consequently, the overall growth and income profile is defined by a lack of current income distribution and a reliance on future clinical successes to drive capital appreciation and eventual profitability.